Mitchell.vonItzstein

Medical oncologist at UT Southwestern Medical Center. Interested in improving patient outcomes through clinical and translational research.

[UTSW Simmons Cancer Center @utswcancer]

A clinical trial led by UTSW researchers found #selinexor, an FDA-approved drug used to treat multiple myeloma and lymphoma, also shrank tumors in #NSCLC with KRAS mutations: https://t.co/1LL02kHHyS.

[Jarushka Naidoo @DrJNaidoo]

Ph 1/2 trial selinexor+docetaxel in adv KRAS+ NSCLC @CCR_AACR:

- selinexor is a XPO1 inhibitor with activity in KRAS+ PDX models, p53 is neg predictor of response
- 40pts, MTD 60mg weekly
- ORR 80 v 27% KRAS+/p53WT v p53+

@OncoAlert @KRASKickers #LCSM

https://t.co/XTbSDqbHkN

[Marlowe S Tessmer @Marlowe_Tessmer]

Hot off the press an interesting Phase 1/2 trial of XPO1 inhibitor selinexor plus docetaxel in previously treated, advanced KRAS mutant non-small cell lung cancer https://t.co/QKaFKkaaZw

[Mitchell.vonItzstein @MVonitzstein]

Our latest clinical trial has been published showing selinexor has promising activity for the treatment of TP53 wild type KRAS mutant NSCLC.

https://t.co/hEpqY3XIO6

https://t.co/ZZ9sqRqk4y

[Mitchell.vonItzstein @MVonitzstein]

@SawsanRashdanMD @AnasAlomarMD Congrats!

[Journal for ImmunoTherapy of Cancer @jitcancer]

New #JITC case report: Humoral and cellular correlates of a novel immune-related adverse event and its treatment https://t.co/YB4SqdnKAP

[Mitchell.vonItzstein @MVonitzstein]

@rmelias2 Congrats!

[COSA @COSAoncology]

Congratulations Mitchell von Itzstein for your excellent presentation amongst a very strong field at #COSA21 #clinicalresearch

Proudly sponsored by @MSD_Aus

[Mitchell.vonItzstein @MVonitzstein]

@COSAoncology @MSD_Aus Thanks! It was a great session!

[Mitchell.vonItzstein @MVonitzstein]

We review the utilization of information technologies in oncology clinical trials. Promising technical developments, but difficult to implement due to the complexity of oncology trials.
https://t.co/ZkPD0ImlML

[Mitchell.vonItzstein @MVonitzstein]

Integration of blood-based biomarkers for lung cancer screening into clinical practice alongside low-dose CT has the potential to improve patient outcomes.
https://t.co/g0lV5WI8qS

[Mitchell.vonItzstein @MVonitzstein]

Our latest study evaluates dosing strategy in patients receiving cancer immunotherapy with immune checkpoint inhibitors. Weight-based dosing appears more effective, particularly for patients with high body mass index.
https://t.co/SYYKRIQMWj

[Mitchell.vonItzstein @MVonitzstein]

Our new study: Next-generation sequencing is increasingly used to inform clinical decisions in oncology practice, but even when actionable tumor molecular alterations are identified, many eligible patients are unable to access approved targeted therapies.
https://t.co/GSEYaMtW5V

[Mitchell.vonItzstein @MVonitzstein]

We present a case of grade 4 immune checkpoint inhibitor induced myositis with a potential association with prior statin induced myopathy and development of anti-HMGCR antibodies.
https://t.co/WSSxx0APdh

[Mitchell.vonItzstein @MVonitzstein]

We review investigational biomarkers for immune checkpoint inhibitor adverse events. Included are useful tables and a figure to review the clinical manifestations and mechanisms underlying these immune related adverse events. https://t.co/OpTJxlhBxe

[Mitchell.vonItzstein @MVonitzstein]

We report an analysis of lung cancer resection outcomes. Modifiable best surgical practices contribute to a substantial proportion of outcome differences between low- and high-volume centers for lung cancer resection.
https://t.co/IVBNRd199v

[Mitchell.vonItzstein @MVonitzstein]

We report an analysis in trends of safety outcomes for lung cancer surgery - increased reporting but decreased mortality
https://t.co/BkuXMkTiXW

[7NEWS Gold Coast @7NewsGoldCoast]

Researchers at @Griffith_Uni are taking a different approach to finding a cure for COVID-19. They’re using live human cells and lungs to test thousands of drugs already on the market. https://t.co/AN25f87H8i @AmandaAbate #coronavirus #7NEWS

[Mitchell.vonItzstein @MVonitzstein]

@PiyushNathani3 @paulk_mi @UTSWIMchief @DinoKazi This is a great idea

[Mitchell.vonItzstein @MVonitzstein]

We publish a late onset immune-related adverse event - checkpoint inhibitor induced Raynaud's phenomenon. Toxicity at 22 months was preceded by dramatic rise in anti-vitronectin antibodies (causes vascular endothelial dysfunction).
https://t.co/VP7FdwT2Hu